Company intelligence / Profile preview

锦波生物

Taiyuan, Shanxi Province, China

Ownership: Private
Employees: ~730
Development stage: Other

Overview

锦波生物 has successfully commercialized multiple products based on its proprietary recombinant humanized type III collagen technology. The company was the first in China to obtain medical device raw material registration for this product. Its products are used in both medical devices and high-end skincare/cosmeceuticals for wound healing and skin repair. The company also develops anti-HPV bio-protein products. Clinical results support efficacy in tissue regeneration and sensitive skin repair

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Recombinant proteinPeptides
Industry: Biotech

Partnerships

Collaborative research with Fudan UniversityChinese Academy of Sciences Institute of BiophysicsSichuan Universityjoint labs with Chongqing Medical University Second Hospital

Beyond the preview

Go deeper on 锦波生物.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 锦波生物.

Explore the full profile